Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A pediatric oncology group phase III trial

Donald H. Mahoney, Jonathan Shuster, Ruprecht Nitschke, Stephen J. Lauer, Naomi Winick, C. Philip Steuber, Bruce Camitta

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Fingerprint

Dive into the research topics of 'Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A pediatric oncology group phase III trial'. Together they form a unique fingerprint.

Medicine & Life Sciences